Statement from FDA Commissioner Scott Gottlieb, M.D. on advancing the development of novel treatments for neurological conditions; part of broader effort on modernizing FDA’s new drug review programs - FDA Press Releases

FDA’s 5 guidance documents provide details for drug development for neurological conditions such as ALS and Alzheimer’s disease

from Food and Drug Administration--Press Releases http://ift.tt/2o7Fr6J
via IFTTT